Practice Areas:

Ms. Wang's practice focuses on life sciences and healthcare, mergers, acquisitions and corporate restructuring, cross-border investment, and corporate compliance.

Ms. Wang has extensive experience in corporate and transactional matters. She has represented numerous Fortune Global 500 companies, USD funds, RMB funds, large state-owned groups, and privately held enterprises in a wide range of transactions, including control acquisitions, equity investments from angel rounds through pre-IPO rounds, establishment of and exit from joint ventures, asset sales and licensing transactions, and offshore listings. She is known for delivering commercially valuable legal solutions with sharp business acumen and outstanding communication skills.

Ms. Wang has deep experience in the healthcare industry. She has provided comprehensive legal services to multinational pharmaceutical groups, domestic innovative drug companies, and medical device companies on matters including R&D, clinical trials, product launch, commercialization, MAH transfers, licensing in/out, ODM/OEM manufacturing, compliance system development, and overseas expansion.

Ms. Wang's major clients have included Ant Health, Bristol Myers Squibb, Fresenius, Johnson & Johnson, Pfizer, Novartis, Philips, CapitaLand, Sinopharm, Connect Biopharma, CStone Pharmaceuticals, Inmagene, WuXi AppTec, NIO, Alibaba Health, XtalPi, Innovusion (Seyond), Ustar Biotechnologies, Goldman Sachs, The Carlyle Group, Temasek, Centurium Capital, CICC Capital, Hillhouse Capital, CBC Group and CPE, among others.

Education:

Ms. Wang received her Bachelor of Science degree from the College of Pharmaceutical Sciences, Zhejiang University, and her Juris Master (Chinese law) and Juris Doctor (U.S. law) degrees from Peking University School of Transnational Law. She is also a member of LawWithoutWalls.

Professional Experience:

Ms. Wang joined T&C Law Firm in 2024. Prior to that, she practiced for many years at Fangda Partners and JunHe LLP, and also served as in-house counsel at Fosun Group and Bristol Myers Squibb.

Selected Publications:

Overview of the Key Amendments to the GCP, June 2026

Bridging Past and Future: Commentary on the Key Amendments to the Implementing Regulations of the Drug Administration Law, February 14, 2026

An Overview of the Current State of AI Healthcare Regulation, December 15, 2025

The Scope and Implications of the Compliance Guidelines on Anti-Commercial Bribery Risks, March 1, 2025

White Paper on Chinese Medical Devices Entering Southeast Asia, October 2024

Swift Waters Ahead: A Brief Commentary on the Medical Device Administration Law (Draft for Comment), September 2024

Gathering Storm: A Close Look at the U.S. BIOSECURE Act, June 2024

Interpretation of the New Regulations on Contract Manufacturing of Medical Devices, May 2024

Representative Matters

Outbound Investment

Represented an A-share listed company in its USD 40 million Series B investment in a U.S.-based innovative drug company

Supported Fosun in its acquisition of a portfolio of ten healthcare property assets across five U.S. states, with a transaction value exceeding USD 200 million, jointly funded by three Fosun-controlled insurance companies located in Portugal, the United States and Hong Kong (work included establishment of the funding platforms, due diligence on the target assets and negotiation of the transaction documents, CFIUS risk analysis, and review of bank loan documents)

Supported Fosun in its acquisition of an internationally renowned medical resort hotel in Switzerland (covering pharmaceutical, health supplement and cosmetics product lines as well as clinical services), involving a 100% equity acquisition and the carve-out of the underlying hotel real estate in favor of a long-term lease model

Represented a Chinese cosmetics company in its acquisition of a local cosmetics brand in Israel

Represented a Chinese metal manufacturing company in its investment in a joint venture in Bangladesh, and assisted the client in successfully completing the ODI procedures

Foreign Direct Investment and M&A

Represented a Chinese special situations investment firm in its acquisition from Blackstone of 100% of the equity in a healthcare group, structured as an offshore red-chip transaction, advising the client throughout on deal structuring, drafting and negotiation of transaction documents, closing and post-closing management

Represented Transfar Group in the establishment of a comprehensive general hospital, participating throughout in the hospital's structuring and the compliance design of its operating model, and represented the joint venture in designing and drafting the entrusted management agreement with Sir Run Run Shaw Hospital

Represented Singapore's CapitaLand in the transfer of several of its commercial real estate holdings, participating throughout in the drafting and negotiation of the transaction documents

Represented a consortium comprising Centurium Capital, CPE, Temasek and Hillhouse Capital in the take-private of China Biologic Products, with a transaction value exceeding USD 4.76 billion (named an IFLR Deal of the Year 2022)

Represented a consortium comprising Primavera Capital, CBC Group and Shanghai Pharmaceuticals in bidding for the China business of a multinational company, involving both an equity transfer and complex asset transfer arrangements

Represented Fresenius in establishing two wholly foreign-owned nephrology specialty hospitals in Xiamen and Quanzhou, Fujian Province, marking the client's first move from medical devices into healthcare services

Represented Fresenius in acquiring two privately owned general hospitals in Kunming, Yunnan Province and Luzhou, Sichuan Province (the former involving conversion from non-profit to for-profit status; the latter a for-profit hospital), and advised on converting the hospitals into nephrology specialty hospitals following the acquisitions

Represented CBC Group in bidding for control of more than ten privately owned hospitals (some converted from state-owned enterprises) held by CITIC PE

Represented CHJ Jewellery in conducting due diligence on all stores (including medical aesthetics clinics) of Siyanli in its proposed acquisition of Siyanli

Represented the Chinese subsidiary of an Israel-headquartered shipping company in receiving a strategic investment from Alibaba and establishing a long-term strategic partnership with Alibaba

Represented a Nasdaq-listed Israeli company in the sale of its equity interest in a Chinese automotive joint venture, with a transaction value exceeding RMB 1.56 billion

Represented Victrex in establishing a joint venture with a local Chinese supplier and advised the joint venture on building a new plant in China (including land acquisition, plant construction, negotiation of government subsidies, and raw material supply)

Represented MBK Partners in the acquisition of three foreign-invested chemical manufacturing companies (as part of the seller's global asset divestiture)

Represented SUEZ in bidding for a controlling stake in a state-controlled solid waste treatment company

Represented Goldman Sachs and The Carlyle Group in conducting due diligence on target properties in several bids for residential and commercial office buildings in China

Represented CITIC PE in a competitive bid for 100% of the equity in Orange Hotels

Equity Investment

Represented an AI image processing company in its USD 30 million angel and Series A financings led by Tencent

Represented a 3D AI model company in its USD 4 million angel round and USD 15 million Series A financing

Represented Yehe Technology in obtaining RMB 10 million seed round investment from Shunwei Capital

Represented RA Capital in its pre-IPO round investment in Connect Biopharma

Represented Hillhouse Capital in incubating and investing in a gene-editing company, including assisting the company in building its VIE structure, securing dedicated local government support, extending onshore bridge loans to the target company and obtaining warrants in the offshore company, and completing ODI procedures for outbound remittance of funds

Represented HighLight Capital in its Series C investment in Inmagene (transaction value of approximately USD 20 million)

Represented CPE and other investors in the Series D and Series E financings of Ustar Biotechnologies (aggregate transaction value exceeding RMB 500 million)

Represented WuXi AppTec in a strategic investment in an insurtech company (aggregate transaction value exceeding RMB 150 million), and assisted the client in forming a joint venture with the target company dedicated to Huiminbao (inclusive commercial health insurance) business

Represented an RMB fund under CICC in its Series B investment in a surgical robotics company (total financing of RMB 540 million)

Represented Qiming Venture Partners in its Series A equity investment in an IoT company

Represented Huiqiao Capital in its Series B equity investment in a genetic testing company

Represented XtalPi in completing its Series D and cross-over USD financings totaling several hundred million U.S. dollars

Represented The Carlyle Group in the restructuring of, and pre-IPO equity investment in, OneSmart Education

Represented Temasek in its Series A and Series B equity investments in NIO

Represented Goldman Sachs in strategic equity investments in several solar and wind power companies

Represented Goldman Sachs in a pre-IPO equity investment in a hardware manufacturing company

Represented SoftBank in its Series D and D+ investments in Beike (KE Holdings), with a transaction value of approximately USD 1.35 billion

Represented Innovusion in completing its Series B financing of USD 64 million

Supported Fosun's cosmetics group in its corporate restructuring, and, following completion of the restructuring, assisted it in completing a Series B financing exceeding RMB 100 million

General Compliance Advisory

Provided day-to-day compliance advice to companies including Huadong Medicine, Mabworks Biotech, Yuhong Pharmaceutical and Huadesen Biotech

Issued compliance analysis for Ant Group in connection with its post-acquisition integration of Haodf.com

Supported the day-to-day legal affairs of Fosun's cosmetics group, including without limitation offline store openings, brand licensing management, product procurement and distribution agreement management, e-commerce platform related legal matters, and employment and dispute resolution

Served as legal counsel to BMS for Mainland China and Hong Kong, providing legal support on product market access, commercial distribution, drug promotion, clinical trials, patient assistance programs, and data compliance